Exelixis (EXEL)
Exelixis on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
27.3M
Short interest
settlement 2026-10-15
11.3
Days to cover
-1.3 days vs prior
61.5%
Short share of volume
2026-10-28
600
Fails to deliver
settlement 2026-09-21
Tue 3 Nov
Next earnings
estimated date
-$527K
Insider flow, 90 days
0 buys, 1 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in EXEL is 27,313,139 shares, up 912,683 shares over the last month. Over the last 48 readings it ranged from 7,328,314 shares (13 December 2024) to 30,913,414 shares (15 July 2026). At the reported average volume of 2.4M shares a day that is 11.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/exel" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 27,313,139 | -3.1% | 2,410,179 | 11.33 |
| 2026-09-30 | 28,183,726 | +6.8% | 2,228,196 | 12.65 |
| 2026-09-15 | 26,400,456 | -7.9% | 2,131,655 | 12.38 |
| 2026-08-31 | 28,656,285 | +2.2% | 1,925,986 | 14.88 |
| 2026-08-14 | 28,031,459 | -2.5% | 3,217,483 | 8.71 |
| 2026-07-31 | 28,749,664 | -7.0% | 2,142,046 | 13.42 |
| 2026-07-15 | 30,913,414 | +8.3% | 2,439,206 | 12.67 |
| 2026-06-30 | 28,539,118 | -6.8% | 3,327,761 | 8.58 |
| 2026-06-15 | 30,635,016 | +3.1% | 2,261,904 | 13.54 |
| 2026-05-29 | 29,707,071 | -1.9% | 2,404,618 | 12.35 |
| 2026-05-15 | 30,278,606 | +0.9% | 3,303,551 | 9.17 |
| 2026-04-30 | 30,010,146 | +6.0% | 2,374,709 | 12.64 |
| 2026-04-15 | 28,306,926 | +3.8% | 2,163,233 | 13.09 |
| 2026-03-31 | 27,263,165 | +3.5% | 2,478,249 | 11.00 |
| 2026-03-13 | 26,352,704 | +0.1% | 3,575,723 | 7.37 |
| 2026-02-27 | 26,323,621 | -8.6% | 2,658,986 | 9.90 |
| 2026-02-13 | 28,805,341 | +3.3% | 2,847,372 | 10.12 |
| 2026-01-30 | 27,879,825 | +8.2% | 2,354,811 | 11.84 |
| 2026-01-15 | 25,766,783 | +4.3% | 2,569,651 | 10.03 |
| 2025-12-31 | 24,704,144 | +8.2% | 2,318,670 | 10.65 |
| 2025-12-15 | 22,834,554 | +6.9% | 2,672,661 | 8.54 |
| 2025-11-28 | 21,360,218 | +6.0% | 2,477,165 | 8.62 |
| 2025-11-14 | 20,145,618 | +1.8% | 3,141,897 | 6.41 |
| 2025-10-31 | 19,791,732 | -5.2% | 3,192,239 | 6.20 |
| 2025-10-15 | 20,882,902 | +17.7% | 2,302,357 | 9.07 |
| 2025-09-30 | 17,746,951 | +0.9% | 2,573,204 | 6.90 |
| 2025-09-15 | 17,593,092 | -0.2% | 2,509,640 | 7.01 |
| 2025-08-29 | 17,632,257 | +4.3% | 2,086,660 | 8.45 |
| 2025-08-15 | 16,898,684 | -2.7% | 3,120,938 | 5.41 |
| 2025-07-31 | 17,367,631 | -4.9% | 4,123,506 | 4.21 |
| 2025-07-15 | 18,267,722 | -5.8% | 2,986,662 | 6.12 |
| 2025-06-30 | 19,381,935 | -4.9% | 4,369,557 | 4.44 |
| 2025-06-13 | 20,385,497 | +9.6% | 2,426,995 | 8.40 |
| 2025-05-30 | 18,607,983 | -0.6% | 3,327,675 | 5.59 |
| 2025-05-15 | 18,723,325 | -2.4% | 4,241,038 | 4.41 |
| 2025-04-30 | 19,183,313 | +5.2% | 2,048,653 | 9.36 |
| 2025-04-15 | 18,230,244 | +22.7% | 2,615,674 | 6.97 |
| 2025-03-31 | 14,855,827 | +12.7% | 2,802,899 | 5.30 |
| 2025-03-14 | 13,181,425 | -0.8% | 2,699,115 | 4.88 |
| 2025-02-28 | 13,286,921 | -17.7% | 2,707,650 | 4.91 |
| 2025-02-14 | 16,147,636 | +23.3% | 2,380,581 | 6.78 |
| 2025-01-31 | 13,094,977 | -9.4% | 2,724,430 | 4.81 |
| 2025-01-15 | 14,456,559 | +38.3% | 2,642,150 | 5.47 |
| 2024-12-31 | 10,450,134 | +42.6% | 2,300,407 | 4.54 |
| 2024-12-13 | 7,328,314 | -12.3% | 1,600,701 | 4.58 |
| 2024-11-29 | 8,357,534 | +5.8% | 1,767,636 | 4.73 |
| 2024-11-15 | 7,902,015 | -13.4% | 2,500,236 | 3.16 |
| 2024-10-31 | 9,120,130 | -8.6% | 2,649,424 | 3.44 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of EXEL volume is 61.5%, up 10.7 points over the last five sessions. Over the last 30 readings it ranged from 39.8% (21 September 2026) to 77.7% (24 September 2026). The latest reading is 2.5 points above the 30-session average of 59.0%, on 588K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 361K | 588K | 61.5% | 0 |
| 2026-10-27 | 306K | 555K | 55.2% | 1,346 |
| 2026-10-26 | 426K | 675K | 63.1% | 1 |
| 2026-10-23 | 407K | 612K | 66.4% | 274 |
| 2026-10-22 | 254K | 505K | 50.3% | 24 |
| 2026-10-21 | 298K | 587K | 50.8% | 0 |
| 2026-10-20 | 419K | 816K | 51.4% | 2,070 |
| 2026-10-19 | 323K | 667K | 48.4% | 25 |
| 2026-10-16 | 551K | 861K | 63.9% | 28,177 |
| 2026-10-15 | 727K | 1.2M | 59.7% | 4,416 |
| 2026-10-14 | 479K | 1.0M | 47.3% | 190 |
| 2026-10-13 | 589K | 1.1M | 55.9% | 9,992 |
| 2026-10-12 | 782K | 1.1M | 71.8% | 1,148 |
| 2026-10-09 | 639K | 1.0M | 62.2% | 1,234 |
| 2026-10-08 | 503K | 820K | 61.4% | 1,220 |
| 2026-10-07 | 599K | 1.2M | 49.6% | 224 |
| 2026-10-06 | 482K | 919K | 52.4% | 652 |
| 2026-10-05 | 417K | 655K | 63.7% | 489 |
| 2026-10-02 | 480K | 724K | 66.3% | 1 |
| 2026-10-01 | 364K | 568K | 64.1% | 21 |
| 2026-09-30 | 749K | 1.2M | 62.8% | 183 |
| 2026-09-29 | 423K | 712K | 59.4% | 10 |
| 2026-09-28 | 192K | 377K | 51.0% | 0 |
| 2026-09-25 | 523K | 718K | 72.8% | 0 |
| 2026-09-24 | 574K | 739K | 77.7% | 1,700 |
| 2026-09-23 | 405K | 579K | 69.9% | 100 |
| 2026-09-22 | 276K | 520K | 53.0% | 100 |
| 2026-09-21 | 317K | 798K | 39.8% | 6,189 |
| 2026-09-18 | 346K | 541K | 64.1% | 0 |
| 2026-09-17 | 292K | 533K | 54.7% | 13,974 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 21 September 2026, the fails-to-deliver balance in EXEL is 600 shares, up 346 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (7 January 2026) to 97,101 shares (9 February 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-21 | 600 | $58.36 | $35K |
| 2026-09-02 | 254 | $56.89 | $14K |
| 2026-08-25 | 1 | $54.55 | $55 |
| 2026-08-24 | 460 | $54.08 | $25K |
| 2026-08-17 | 88,384 | $51.24 | $4.5M |
| 2026-08-12 | 479 | $51.33 | $25K |
| 2026-08-04 | 25,835 | $55.06 | $1.4M |
| 2026-07-31 | 619 | $55.97 | $35K |
| 2026-07-30 | 1,439 | $55.33 | $80K |
| 2026-07-20 | 182 | $55.92 | $10K |
| 2026-07-16 | 51 | $55.55 | $3K |
| 2026-07-13 | 166 | $56.50 | $9K |
| 2026-07-09 | 46,549 | $56.11 | $2.6M |
| 2026-07-06 | 400 | $55.85 | $22K |
| 2026-06-15 | 32 | $53.13 | $2K |
| 2026-06-04 | 57,234 | $51.60 | $3.0M |
| 2026-05-19 | 179 | $49.84 | $9K |
| 2026-04-07 | 2,151 | $43.98 | $95K |
| 2026-03-31 | 7,235 | $41.95 | $304K |
| 2026-03-20 | 515 | $41.26 | $21K |
| 2026-03-02 | 251 | $44.06 | $11K |
| 2026-02-26 | 357 | $44.75 | $16K |
| 2026-02-25 | 204 | $45.14 | $9K |
| 2026-02-23 | 80 | $43.63 | $3K |
| 2026-02-11 | 195 | $42.98 | $8K |
| 2026-02-09 | 97,101 | $43.90 | $4.3M |
| 2026-02-03 | 22,890 | $42.81 | $980K |
| 2026-01-20 | 1,100 | $43.96 | $48K |
| 2026-01-13 | 60,641 | $44.06 | $2.7M |
| 2026-01-07 | 1 | $43.68 | $44 |
Insider trades
SEC Form 4, newest first. JSONInsiders at EXEL reported 1 open-market sell worth $527K in the last 90 days and no open-market buys. Latest filing: Beckerle Mary C (Director) on 2026-08-10.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | Beckerle Mary C | Director | Sell | 10K | $53.66 | $527K | 16K |
| 2026-06-01 | WYSZOMIERSKI JACK L | Director | Sell | 4K | $50.55 | $198K | 284K |
| 2026-06-01 | Eckhardt Sue Gail | Director | Sell | 10K | $50.14 | $492K | 16K |
| 2026-05-27 | PAPADOPOULOS STELIOS | Director | Grant | 8K | $0.00 | $0 | 1.2M |
| 2026-05-27 | Heyman Tomas J. | Director | Grant | 8K | $0.00 | $0 | 51K |
| 2026-05-27 | Eckhardt Sue Gail | Director | Grant | 8K | $0.00 | $0 | 26K |
| 2026-05-27 | Smith Julie | Director | Grant | 8K | $0.00 | $0 | 29K |
| 2026-05-27 | Freire Maria C | Director | Grant | 8K | $0.00 | $0 | 109K |
| 2026-05-27 | Oliver Bob | Director | Grant | 8K | $0.00 | $0 | 29K |
| 2026-05-27 | WYSZOMIERSKI JACK L | Director | Grant | 8K | $0.00 | $0 | 288K |
| 2026-05-27 | POSTE GEORGE | Director | Grant | 8K | $0.00 | $0 | 127K |
| 2026-05-27 | Beckerle Mary C | Director | Grant | 8K | $0.00 | $0 | 26K |
| 2026-05-26 | Aftab Dana | EVP, Research and Development | Sell | 43K | $50.35 | $2.2M | 595K |
| 2026-05-20 | Haley Patrick J. | EVP, Commercial | Sell | 32K | $49.81 | $1.6M | 358K |
| 2026-05-18 | MORRISSEY MICHAEL | President and CEO | Gift | 124K | $0.00 | $0 | 2.0M |
| 2026-05-18 | MORRISSEY MICHAEL | President and CEO | Gift | 124K | $0.00 | $0 | 1.4M |
| 2026-05-18 | Senner Christopher J. | EVP and CFO | Sell | 35K | $50.00 | $1.7M | 952K |
| 2026-05-18 | Hefti Brenda | SVP and General Counsel | Sell | 7K | $50.21 | $333K | 107K |
| 2026-05-15 | MORRISSEY MICHAEL | President and CEO | Tax withholding | 128K | $51.10 | $6.6M | 1.5M |
| 2026-05-15 | Senner Christopher J. | EVP and CFO | Tax withholding | 41K | $51.10 | $2.1M | 987K |
| 2026-05-15 | Haley Patrick J. | EVP, Commercial | Tax withholding | 33K | $51.10 | $1.7M | 390K |
| 2026-05-15 | Hefti Brenda | SVP and General Counsel | Tax withholding | 6K | $51.10 | $328K | 113K |
| 2026-05-15 | Aftab Dana | EVP, Research and Development | Tax withholding | 31K | $51.10 | $1.6M | 638K |
| 2026-05-07 | Freire Maria C | Director | Sell | 21K | $46.00 | $949K | 101K |
| 2026-05-07 | Freire Maria C | Director | Exercise or conversion | 21K | $19.77 | $408K | 121K |
| 2026-05-07 | POSTE GEORGE | Director | Sell | 60K | $45.71 | $2.7M | 119K |
| 2026-05-07 | Beckerle Mary C | Director | Sell | 8K | $48.45 | $374K | 18K |
| 2026-05-07 | Beckerle Mary C | Director | Exercise or conversion | 4K | $23.24 | $90K | 25K |
| 2026-05-06 | MORRISSEY MICHAEL | President and CEO | Gift | 110K | $0.00 | $0 | 1.9M |
| 2026-02-26 | Senner Christopher J. | EVP and CFO | Grant | 52K | $0.00 | $0 | 1.0M |
| 2026-02-26 | Hefti Brenda | SVP and General Counsel | Grant | 23K | $0.00 | $0 | 120K |
| 2026-02-26 | Haley Patrick J. | EVP, Commercial | Grant | 40K | $0.00 | $0 | 422K |
| 2026-02-26 | MORRISSEY MICHAEL | President and CEO | Grant | 160K | $0.00 | $0 | 1.6M |
| 2026-02-26 | Aftab Dana | EVP, Research and Development | Grant | 52K | $0.00 | $0 | 668K |
| 2026-02-24 | Aftab Dana | EVP, Research and Development | Sell | 48K | $44.50 | $2.1M | 616K |
| 2026-02-24 | MORRISSEY MICHAEL | President and CEO | Gift | 100K | $0.00 | $0 | 2.0M |
| 2026-02-19 | Aftab Dana | EVP, Research and Development | Sell | 30K | $44.35 | $1.3M | 664K |
| 2026-02-18 | MORRISSEY MICHAEL | President and CEO | Gift | 125K | $0.00 | $0 | 2.1M |
| 2026-02-18 | MORRISSEY MICHAEL | President and CEO | Gift | 125K | $0.00 | $0 | 1.5M |
| 2026-02-18 | Hefti Brenda | SVP and General Counsel | Sell | 19K | $44.01 | $822K | 97K |
| 2026-02-18 | Smith Julie | Director | Sell | 20K | $44.30 | $887K | 21K |
| 2026-02-18 | Smith Julie | Director | Exercise or conversion | 20K | $21.69 | $434K | 41K |
| 2026-02-18 | Smith Julie | Director | Sell | 44K | $44.50 | $2.0M | 21K |
| 2026-02-18 | Smith Julie | Director | Exercise or conversion | 44K | $19.39 | $855K | 65K |
| 2026-02-18 | WYSZOMIERSKI JACK L | Director | Sell | 100K | $44.01 | $4.4M | 280K |
| 2026-02-18 | WYSZOMIERSKI JACK L | Director | Exercise or conversion | 21K | $19.77 | $408K | 380K |
| 2026-02-17 | MORRISSEY MICHAEL | President and CEO | Gift | 251K | $0.00 | $0 | 2.0M |
| 2026-02-17 | Senner Christopher J. | EVP and CFO | Sell | 31K | $43.67 | $1.3M | 976K |
| 2026-02-17 | Haley Patrick J. | EVP, Commercial | Sell | 65K | $43.50 | $2.8M | 382K |
| 2026-02-17 | Haley Patrick J. | EVP, Commercial | Sell | 3K | $43.84 | $133K | 447K |
| 2026-02-17 | MORRISSEY MICHAEL | President and CEO | Gift | 251K | $0.00 | $0 | 1.6M |
| 2026-02-17 | Smith Julie | Director | Sell | 42K | $43.33 | $1.8M | 21K |
| 2026-02-17 | Smith Julie | Director | Exercise or conversion | 42K | $18.19 | $772K | 63K |
| 2026-02-15 | Senner Christopher J. | EVP and CFO | Tax withholding | 36K | $43.92 | $1.6M | 1.0M |
| 2026-02-15 | Haley Patrick J. | EVP, Commercial | Tax withholding | 31K | $43.92 | $1.4M | 450K |
| 2026-02-15 | MORRISSEY MICHAEL | President and CEO | Tax withholding | 120K | $43.92 | $5.3M | 1.8M |
| 2026-02-15 | Hefti Brenda | SVP and General Counsel | Tax withholding | 5K | $43.92 | $238K | 115K |
| 2026-02-15 | Aftab Dana | EVP, Research and Development | Tax withholding | 13K | $43.92 | $559K | 694K |
| 2026-02-15 | Aftab Dana | EVP, Research and Development | Tax withholding | 26K | $43.92 | $1.2M | 707K |
| 2026-02-13 | Senner Christopher J. | EVP and CFO | Sell | 34K | $43.00 | $1.5M | 1.0M |
| 2026-02-13 | MORRISSEY MICHAEL | President and CEO | Tax withholding | 370K | $43.92 | $16.2M | 2.0M |
| 2026-02-13 | MORRISSEY MICHAEL | President and CEO | Exercise or conversion | 495K | $21.31 | $10.5M | 2.3M |
| 2026-02-13 | Eckhardt Sue Gail | Director | Sell | 4K | $43.79 | $169K | 18K |
| 2026-02-13 | Oliver Bob | Director | Sell | 21K | $43.90 | $929K | 21K |
| 2026-02-13 | Oliver Bob | Director | Sell | 9K | $43.61 | $396K | 42K |
| 2026-02-13 | Oliver Bob | Director | Exercise or conversion | 9K | $19.28 | $175K | 51K |
| 2026-01-15 | MORRISSEY MICHAEL | President and CEO | Tax withholding | 140K | $45.23 | $6.3M | 1.8M |
| 2026-01-15 | MORRISSEY MICHAEL | President and CEO | Grant | 548K | $0.00 | $0 | 2.0M |
| 2026-01-15 | Haley Patrick J. | EVP, Commercial | Tax withholding | 32K | $45.23 | $1.5M | 481K |
| 2026-01-15 | Haley Patrick J. | EVP, Commercial | Grant | 140K | $0.00 | $0 | 514K |
| 2026-01-15 | Senner Christopher J. | EVP and CFO | Tax withholding | 40K | $45.23 | $1.8M | 1.1M |
| 2026-01-15 | Senner Christopher J. | EVP and CFO | Grant | 149K | $0.00 | $0 | 1.1M |
| 2026-01-15 | Aftab Dana | EVP, Research and Development | Tax withholding | 27K | $45.23 | $1.2M | 733K |
| 2026-01-15 | Aftab Dana | EVP, Research and Development | Grant | 120K | $0.00 | $0 | 760K |
| 2025-12-03 | Hefti Brenda | SVP and General Counsel | Grant | 30K | $0.00 | $0 | 121K |
| 2025-11-25 | Caligan Partners LP | Director,Other | Buy | 28K | $43.12 | $1.2M | 1.6M |
| 2025-11-25 | JOHNSON DAVID EDWARD | Director | Buy | 28K | $43.12 | $1.2M | 1.6M |
| 2025-11-21 | Haley Patrick J. | EVP, Commercial | Sell | 28K | $42.58 | $1.2M | 374K |
| 2025-11-21 | Aftab Dana | EVP, Research and Development | Gift | 24K | $0.00 | $0 | 641K |
| 2025-11-20 | Haley Patrick J. | EVP, Commercial | Sell | 11K | $41.77 | $445K | 0 |
| 2025-11-20 | Haley Patrick J. | EVP, Commercial | Sell | 24K | $41.93 | $987K | 0 |
| 2025-11-20 | Haley Patrick J. | EVP, Commercial | Sell | 10K | $42.11 | $421K | 402K |
| 2025-11-17 | Oliver Bob | Director | Gift | 1K | $0.00 | $0 | 42K |
| 2025-11-12 | MORRISSEY MICHAEL | President and CEO | Gift | 102K | $0.00 | $0 | 1.8M |
| 2025-11-12 | PAPADOPOULOS STELIOS | Director | Sell | 100K | $43.55 | $4.4M | 1.2M |
| 2025-11-12 | MORRISSEY MICHAEL | President and CEO | Gift | 80K | $0.00 | $0 | 1.7M |
| 2025-11-12 | MORRISSEY MICHAEL | President and CEO | Gift | 102K | $0.00 | $0 | 1.4M |
| 2025-11-11 | MORRISSEY MICHAEL | President and CEO | Gift | 160K | $0.00 | $0 | 1.7M |
| 2025-11-11 | Beckerle Mary C | Director | Sell | 19K | $41.90 | $789K | 21K |
| 2025-11-11 | Beckerle Mary C | Director | Sell | 6K | $42.03 | $243K | 40K |
| 2025-11-11 | Beckerle Mary C | Director | Exercise or conversion | 6K | $23.24 | $134K | 46K |
| 2025-11-11 | Aftab Dana | EVP, Research and Development | Sell | 48K | $42.50 | $2.1M | 665K |
| 2025-10-08 | Aftab Dana | EVP, Research & Development | Grant | 51K | $0.00 | $0 | 713K |
| 2025-06-03 | WYSZOMIERSKI JACK L | Director | Sell | 8K | $43.09 | $325K | 359K |
| 2025-06-02 | Eckhardt Sue Gail | Director | Sell | 4 | $43.67 | $175 | 21K |
| 2025-06-02 | Eckhardt Sue Gail | Director | Sell | 19K | $42.74 | $805K | 21K |
| 2025-05-29 | Smith Julie | Director | Grant | 10K | $0.00 | $0 | 21K |
| 2025-05-29 | Eckhardt Sue Gail | Director | Grant | 10K | $0.00 | $0 | 40K |
| 2025-05-29 | PAPADOPOULOS STELIOS | Director | Grant | 10K | $0.00 | $0 | 1.3M |
| 2025-05-29 | Freire Maria C | Director | Grant | 10K | $0.00 | $0 | 101K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON30 Form 144 notices on file for EXEL worth $49.7M at the prices reported; 1 in the last 90 days worth $526K. Latest: MARY BECKERLE filed on 2026-08-10 to sell 9,812 shares ($526K) from 2026-08-10.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-10 | MARY BECKERLEDirector | 10K | $526K | 0.004% | 2026-08-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-01 | Eckhardt Sue GailDirector | 10K | $499K | 0.004% | 2026-06-01 | UBS Financial Services, Inc. |
| 2026-06-01 | JACK L WYSZOMIERSKIDirector | 4K | $198K | 0.002% | 2026-06-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-26 | DANA T AFTABOfficer | 43K | $2.2M | 0.017% | 2026-05-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-20 | PATRICK JOSEPH HALEYOfficer | 32K | $1.6M | 0.013% | 2026-05-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-18 | CHRISTOPHER J SENNEROfficer | 35K | $1.7M | 0.014% | 2026-05-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-18 | BRENDA JOY HEFTIOfficer | 7K | $333K | 0.003% | 2026-05-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-14 | BOMBORA RISE FOUNDATIONFamily foundation of the CEO of EXEL. | 100K | $5.1M | 0.040% | 2026-05-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-07 | GEORGE H POSTEDirector | 60K | $2.7M | 0.024% | 2026-05-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-07 | MARIA C FREIREDirector | 21K | $949K | 0.008% | 2026-05-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-07 | MARY BECKERLEDirector | 8K | $374K | 0.003% | 2026-05-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-24 | DANA T AFTABOfficer | 48K | $2.1M | 0.018% | 2026-02-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-19 | DANA T AFTABOfficer | 30K | $1.3M | 0.012% | 2026-02-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-18 | JULIE ANNE SMITHDirector | 64K | $2.8M | 0.025% | 2026-02-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-18 | BRENDA JOY HEFTIOfficer | 19K | $822K | 0.007% | 2026-02-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-18 | JACK L WYSZOMIERSKIDirector | 100K | $4.4M | 0.038% | 2026-02-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-17 | JULIE ANNE SMITHDirector | 42K | $1.9M | 0.016% | 2026-02-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-17 | CHRISTOPHER J SENNEROfficer | 31K | $1.3M | 0.012% | 2026-02-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-17 | PATRICK JOSEPH HALEYOfficer | 68K | $3.0M | 0.026% | 2026-02-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-13 | Eckhardt Sue GailDirector | 4K | $165K | 0.001% | 2026-02-13 | UBS Financial Services, Inc. |
| 2026-02-13 | CHRISTOPHER J SENNEROfficer | 34K | $1.5M | 0.013% | 2026-02-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-13 | ROBERT L OLIVERDirector | 30K | $1.3M | 0.012% | 2026-02-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-12 | BOMBORA RISE FOUNDATIONFamily foundation of the CEO of EXEL. | 5K | $216K | 0.002% | 2026-02-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-12 | Haley Patrick J.Officer, Member of immediate family of any of the foregoing | 11K | $445K | 0.004% | 2025-11-20 | Fidelity Investments |
| 2025-11-20 | PATRICK JOSEPH HALEYOfficer | 10K | $421K | 0.004% | 2025-11-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-13 | JEFFREY J HESSEKIELOfficer | 40K | $1.7M | 0.015% | 2025-11-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-12 | Stelios PapadopoulosDirector | 100K | $4.4M | 0.037% | 2025-11-12 | UBS Financial Services Inc |
| 2025-11-12 | JEFFREY J HESSEKIELOfficer | 60K | $2.6M | 0.022% | 2025-11-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-12 | MARY BECKERLEDirector | 25K | $1.0M | 0.009% | 2025-11-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-12 | DANA T AFTABOfficer | 48K | $2.1M | 0.018% | 2025-11-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON17 holders report 5% or more of EXEL in their latest filing, 16 on Schedule 13D (active intent). The largest reported stake is Warren, John R. at 5.6% of the class (13,989,010 shares), filed 2026-08-14 for an event on 2026-08-14.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13D/Ano. 8 | Warren, John R.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Wehrly, Mark C.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon Capital Management, L.L.C.investment adviser, other entity | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Dapice Joshua J.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Dreyfuss, Philip D.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Dunn Hannah E.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Gehani, Varun N.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Giauque, Nicolasindividual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Husen, Avner A.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Kim, David T.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Linn, Michael G.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Luo Patrick (Cheng)individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Roberts, Jr., Thomas G.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Saito Edric C.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Short Daniel S.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Spokes, Andrew J. M.individual | 14.0M | 5.6% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon Capital Partners, L.P.partnership | 0 | 0.0% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon Capital Institutional Partners, L.P.partnership | 0 | 0.0% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon Capital Institutional Partners II, L.P.partnership | 0 | 0.0% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon Capital Institutional Partners III, L.P.partnership | 0 | 0.0% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Four Crossings Institutional Partners V, L.P.partnership | 0 | 0.0% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon Capital Offshore Investors II, L.P.partnership | 0 | 0.0% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon Capital (AM) Investors, L.P.partnership | 0 | 0.0% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon Capital F5 Master I, L.P.partnership | 0 | 0.0% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon Healthcare Partners Master, L.P.partnership | 0 | 0.0% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon Partners, L.L.C.other entity | 0 | 0.0% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon Institutional (GP) V, L.L.C.other entity | 0 | 0.0% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon F5 (GP), L.L.C.other entity | 0 | 0.0% | 2026-08-14 |
| 2026-08-14 | 13D/Ano. 8 | Farallon Healthcare Partners (GP), L.L.C.other entity | 0 | 0.0% | 2026-08-14 |
| 2026-08-12 | 13G/Ano. 1 | AQR Capital Management, LLCinvestment adviser | 11.0M | 4.4% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 1 | AQR Capital Management Holdings, LLCparent holding company | 11.0M | 4.4% | 2026-06-30 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 13.2M | 5.1% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 12 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-01-05 | 13D/Ano. 7 | Fried, Richard Bindividual | 0 | 0.0% | 2026-01-01 |
| 2026-01-05 | 13D/Ano. 7 | Seybold, Williamindividual | 0 | 0.0% | 2026-01-01 |
| 2026-01-05 | 13D/Ano. 7 | Patel, Rajiv A.individual | 0 | 0.0% | 2026-01-01 |
13F holders
Tracked managers holding EXEL at their latest 13F. JSON8 of the 30 tracked managers held EXEL at their latest 13F, $1.96B in total at quarter-end prices. Renaissance Technologies is the largest at $730.6M (1.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 13.4M | $730.6M | 1.01% | -299K |
| AQR Capital Management | 2026-06-30 | 11.0M | $598.6M | 0.21% | -2.1M |
| D. E. Shaw & Co. | 2026-06-30 | 5.6M | $302.1M | 0.14% | +1.9M |
| Two Sigma Investments | 2026-06-30 | 4.2M | $229.1M | 0.17% | +2.0M |
| Millennium Management | 2026-06-30 | 1.2M | $66.3M | 0.02% | +284K |
| Bridgewater Associates | 2026-06-30 | 401K | $21.8M | 0.09% | -80K |
| Fisher Asset Management | 2026-06-30 | 196K | $10.6M | 0.00% | +31K |
| Citadel Advisors | 2026-06-30 | 71K | $3.9M | 0.00% | -741K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-07-03) Exelixis reported revenue of $628.7M, up 10.6% from the same quarter a year earlier, and net income of $212.1M (0.82 diluted EPS). In FY 2025 it generated $884.3M of operating cash flow and spent $947.5M on buybacks.
- Cash
- $281.4M
- Equity
- $1.84B
- Total assets
- $2.49B
- Shares outstanding
- 247,781,692
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-07-03 | $628.7M | $212.1M | 33.7% | 0.82 |
| Q1 FY 2026 | 2026-04-03 | $610.8M | $210.5M | 34.5% | 0.79 |
| Q4 FY 2025derived | 2026-01-02 | $598.7M | $244.5M | 40.8% | n/a |
| Q3 FY 2025 | 2025-10-03 | $597.8M | $193.6M | 32.4% | 0.69 |
| Q2 FY 2025 | 2025-07-04 | $568.3M | $184.8M | 32.5% | 0.65 |
| Q1 FY 2025 | 2025-04-04 | $555.4M | $159.6M | 28.7% | 0.55 |
| Q4 FY 2024derived | 2025-01-03 | $566.8M | $139.9M | 24.7% | n/a |
| Q3 FY 2024 | 2024-09-27 | $539.5M | $118.0M | 21.9% | 0.40 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2026-01-02 | $2.32B | $782.6M | $884.3M | $8.4M | $947.5M | n/a |
| FY 2024 | 2025-01-03 | $2.17B | $521.3M | $700.0M | $28.4M | $652.0M | n/a |
| FY 2022 | 2023-12-29 | $1.83B | $207.8M | $333.3M | $40.5M | $550.4M | n/a |
| FY 2021 | 2022-12-30 | $1.61B | $182.3M | $362.6M | $27.7M | $0 | n/a |
| FY 2020 | 2021-12-31 | $1.43B | $231.1M | $400.8M | $54.2M | $0 | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-07-03; shares outstanding as of 2026-07-27 from the cover page.
What this page is
Exelixis in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Exelixis (EXEL), SEC CIK 939767, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-21.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-10.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-07-03.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-10.JSON and CSV
- Company record
- EDGAR filing index for CIK 939767Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
Datasets
Frequently Asked Questions
How much of EXEL is sold short?
27,313,139 shares were held short at the 2026-10-15 settlement, 11.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is EXEL's daily short volume?
On 2026-10-28, 361,458 of the 587,719 EXEL shares reported to FINRA were sold short, 61.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does EXEL have fails to deliver?
The SEC's latest file shows 600 EXEL shares failed to deliver at settlement 2026-09-21. Fails are reported per settlement date and published twice a month with a lag.
Are EXEL insiders buying or selling?
Insiders at EXEL reported 1 open-market sell worth $527K in the last 90 days and no open-market buys. Latest filing: Beckerle Mary C (Director) on 2026-08-10.
Have EXEL insiders filed to sell?
30 Form 144 notices on file for EXEL worth $49.7M at the prices reported; 1 in the last 90 days worth $526K. Latest: MARY BECKERLE filed on 2026-08-10 to sell 9,812 shares ($526K) from 2026-08-10.
Who owns 5% or more of EXEL?
17 holders report 5% or more of EXEL in their latest filing, 16 on Schedule 13D (active intent). The largest reported stake is Warren, John R. at 5.6% of the class (13,989,010 shares), filed 2026-08-14 for an event on 2026-08-14.
What did EXEL report last quarter?
In Q2 FY 2026 (quarter ended 2026-07-03) Exelixis reported revenue of $628.7M, up 10.6% from the same quarter a year earlier, and net income of $212.1M (0.82 diluted EPS). In FY 2025 it generated $884.3M of operating cash flow and spent $947.5M on buybacks.
Which tracked 13F managers own EXEL?
8 of the 30 tracked 13F managers held EXEL shares at their latest filing, $1.96B in all. The largest: Renaissance Technologies (13.4M shares, $730.6M), Cliff Asness's AQR Capital Management (11.0M shares, $598.6M), D. E. Shaw & Co. (5.6M shares, $302.1M), Two Sigma Investments (4.2M shares, $229.1M), Izzy Englander's Millennium Management (1.2M shares, $66.3M), Ray Dalio's Bridgewater Associates (401K shares, $21.8M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.